Receptor for Advanced Glycation End Products
"Receptor for Advanced Glycation End Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. It also binds AMYLOID BETA PEPTIDES and the ALARMINS - S100A12 and S100 CALCIUM BINDING PROTEIN BETA SUBUNIT.
| Descriptor ID |
D000067759
|
| MeSH Number(s) |
D12.776.543.750.615
|
| Concept/Terms |
Receptor for Advanced Glycation End Products- Receptor for Advanced Glycation End Products
- AGE Receptor
- Receptor, AGE
- RAGE (Receptor for Advanced Glycation End Products)
- Advanced Glycosylation End Product Receptors
- Advanced Glycosylation End-Product Receptor
- Advanced Glycosylation End Product Receptor
- Advanced Glycosylation End-Product Receptors
- Advanced Glycosylation Endproduct Receptors
- Receptor for Advanced Glycation End Products (RAGE)
- Receptor for Advanced Glycation Endproducts
- Receptor, Advanced Glycosylation End-Product
- Receptor, Advanced Glycosylation End Product
- Receptor, Advanced Glycosylation End-Products
- Receptor, Advanced Glycosylation End Products
- Advanced Glycosylation End Product-Specific Receptor
- Advanced Glycosylation End Product Specific Receptor
- AGER Protein
- Protein, AGER
- Amphoterin Receptor
- Receptor, Amphoterin
|
Below are MeSH descriptors whose meaning is more general than "Receptor for Advanced Glycation End Products".
Below are MeSH descriptors whose meaning is more specific than "Receptor for Advanced Glycation End Products".
This graph shows the total number of publications written about "Receptor for Advanced Glycation End Products" by people in this website by year, and whether "Receptor for Advanced Glycation End Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor for Advanced Glycation End Products" by people in Profiles.
-
Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).
-
Commentary: RAGE against the spleen. J Thorac Cardiovasc Surg. 2019 06; 157(6):2272-2273.
-
Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity. J Histochem Cytochem. 2018 04; 66(4):213-227.
-
Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science. 2017 12 01; 358(6367).
-
Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein. Arterioscler Thromb Vasc Biol. 2016 06; 36(6):1101-13.
-
S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner. Arterioscler Thromb Vasc Biol. 2014 Jul; 34(7):1399-411.
-
IL-22 is induced by S100/calgranulin and impairs cholesterol efflux in macrophages by downregulating ABCG1. J Lipid Res. 2014 Mar; 55(3):443-54.
-
A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease. Artif Organs. 2014 Jun; 38(6):474-83.
-
The role of S100B in the interaction between adipocytes and macrophages. Obesity (Silver Spring). 2014 Feb; 22(2):371-9.
-
Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013 May; 228(1):69-79.